The model's full reasoning — Q4 2017 call → NOWe need answer YES/NO. Need analyze transcript. Need determine if management describes identifiable piece of new business activity already started contributing partway through reported period or starting right now, and reported results captured only partial early slice, fuller run-rate arriving over next few quarters as timing matter. We need use only transcript. Let's parse. Company Intra-Cellular Therapies, development stage? Q4 2017 results. They have no approved products? They are preparing NDA for lumateperone. Revenue? Probably no product revenue. They discuss clinical trials, expenses. "New business activity" could be clinical trial? But question asks business activity contributing revenue? Need identify. Management discusses achievements: lumateperone development, ITI-214, ITI-333. They initiated Phase 1/2 trial for ITI-214 in Parkinson's disease late last year. "Clinical conduct of the third cohort is ongoing, following completion of the first and second cohorts with no safety concerns identified. We anticipate topline results will be available in second half of 2018." This is a clinical trial, not business revenue. Not "contributing" to financial results. They also started heart failure study, patient enrollment begins this month. Not revenue. They mention "we ended year with $464.3 million cash" and expect spend $180-200 million in 2018. No new business activity contributing revenue. Maybe "pre-commercial activities" for lumateperone? They hired Head of Commercial Development late last year, building commercial organization. But not revenue, not partial slice. Question asks "new business activity that has ALREADY STARTED CONTRIBUTING PARTWAY THROUGH THE REPORTED PERIOD OR IS STARTING RIGHT NOW" and "reported results captured only a PARTIAL, EARLY SLICE of it, with fuller run-rate arriving over next few quarters as a matter of timing." This sounds like a company with a new product launch, contract, facility. But transcript is biotech with no product revenue. They are spending on R&D. No mention of revenue. So answer NO. Need be careful: Could "new business activity" be "ITI-214 Phase 1/2 trial" as activity? But it's not business contributing revenue; it's clinical development. The question likely from framework about "new business activity" in earnings calls, e.g., new contract, new product. Here no. Let's verify all management statements.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| WHF | WhiteHorse Finance | Q1 2022 | 2022-05-10 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| WTS | Watts Water Technologies, Inc. | Q4 2016 | 2017-02-10 | B |
SHOO · Q1 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the Schwartz & Benjamin acquisition as a new contributor that began delivering sales in the reported Q1 period ($14 million, slightly above plan), with the results capturing only its early partial slice. Management explicitly notes that the full-quarter impact will arrive in subsequent quarters (dragging gross margin more going forward), 2017 will be breakeven-to-EPS, and meaningful profit contribution starts in 2018—making the fuller run-rate a pure timing matter of integration and ramp rather than any further winning. This meets all three criteria. (Madden NYC and SM Europe are also new launches/JVs with early/modest contributions and growth ahead, but Schwartz & Benjamin is the clearest fit for the exact timing story.) NO for the other items because they are either not yet live (China JV), not described as partial/early-slice (SM Europe international growth), or not framed as timing-driven ramp (Madden NYC modest contribution is positive but 2018+ profit is more about execution than pure timing). The answer is YES.
AFL · Q2 2023 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the WINGS cancer insurance product launch in Japan Post (early April, during Q2) as a new, nameable contributor that began transacting mid-period. Management explicitly states it was the "majority contributor" to the 60% cancer sales increase in Q2 versus 2022, 26.6% overall sales premium growth, and notes the reported results captured only an early slice because "right when you launch the product, you'll have an immediate jump in sales in the early months followed by a calming down" with "still much more runway...
PDCO · Q3 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes Heartland Dental as a new customer relationship that began contributing in January (during the reported Q3 period), with the rollout completed on schedule and the business now "getting close to being fully operational." Management explicitly notes that this was "not a significant contributor to consumable sales in the third quarter" — confirming the reported results captured only a partial, early slice — while highlighting the "outstanding start" and excitement for further growth as the relationship scales.